. 2019 Nov 22;5(11):e000316. doi: 10.1099/mgen.0.000316

Table 1.

Frequency of antimicrobial resistance by GAS disease classification

Resistance phenotype	INV (%) [n=263]	SSTI (%) [n=235]	PHG (%) [n=431]	Total (%) [n=929]
M/MLS M cMLS iMLS	26 (9.9)* 6 (2.3) 8 (3.0) 12 (4.6)	22 (9.4) – 4 (1.7) 18 (7.7)	17 (3.9)† 6 (1.4) 2 (0.5) 9 (2.1)	65 (7.0) 12 (1.3) 14 (1.5) 39 (4.2)
TE	15 (5.7)	20 (8.3)*	17 (3.9)†	52 (5.6)
TOTAL‡	33 (12.5)*	34 (14.5)*	33 (7.7)†	100 (10.8)

Resistance phenotype

INV (%)

[n=263]

SSTI (%)

[n=235]

PHG (%)

[n=431]

Total (%)

[n=929]

M/MLS

cMLS

iMLS

26 (9.9)*

6 (2.3)

8 (3.0)

12 (4.6)

22 (9.4)

–

4 (1.7)

18 (7.7)

17 (3.9)†

6 (1.4)

2 (0.5)

9 (2.1)

65 (7.0)

12 (1.3)

14 (1.5)

39 (4.2)

15 (5.7)

20 (8.3)*

17 (3.9)†

52 (5.6)

TOTAL‡

33 (12.5)*

34 (14.5)*

33 (7.7)†

100 (10.8)

*P<0.05 (Fisher’s exact test) compared to pharyngitis.

†P<0.05 (Fisher’s exact test) compared to combined non-pharyngeal (invasive+SSTI).

‡Total includes 6 GAS isolates with resistance to chloramphenicol (n=5) and levofloxacin (n=1).

cMLS, Constitutive MLS; iMLS, inducible MLS; INV, invasive; M, macrolide; MLS, macrolide-lincosamide-streptogramin; PHG, pharyngeal; TE, tetracycline.